Product Description
BEN-34712 is an oral, potent and selective brain penetrant RARab (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. (Sourced from: https://www.sheffield.ac.uk/neuroscience-institute/news/benevolentai-progresses-ben-34712-potential-treatment-als-ind-enabling-studies)
Mechanisms of Action: RARab Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BenevolentAI Bio
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Amyotrophic Lateral Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/05/2023 |
News Article |
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies |